Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma
| Autor: | Yee Chao, Yi Tzen Chen, Chien Wei Su, Chung Pin Li, Yi Hsiang Huang, Fa-Yauh Lee, Han-Chieh Lin, Pei Chang Lee, Ming Chih Hou, Teh Ia Huo, Mei Hsuan Lee |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
Sorafenib Oncology medicine.medical_specialty Carcinoma Hepatocellular Clinical Decision-Making Salvage therapy Antineoplastic Agents Serum Albumin Human 03 medical and health sciences 0302 clinical medicine Predictive Value of Tests Risk Factors Internal medicine Biomarkers Tumor medicine Humans Treatment Failure Derivation Aged Neoplasm Staging Retrospective Studies Hepatology business.industry Standard treatment Liver Neoplasms Hazard ratio Reproducibility of Results Bilirubin Middle Aged medicine.disease BCLC Stage Surgery 030220 oncology & carcinogenesis Hepatocellular carcinoma Retreatment Disease Progression Female 030211 gastroenterology & hepatology business Progressive disease medicine.drug |
| Zdroj: | Liver International. 38:321-330 |
| ISSN: | 1478-3223 |
| DOI: | 10.1111/liv.13527 |
| Popis: | Background and Aims Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) but is challenging after treatment failure. Appropriate criteria for enrolling patients into second-line trials are still limited. In this study, we aimed to establish more objective criteria based on Albumin-Bilirubin (ALBI) grade to select patients with better post-progression survival (PPS) for second-line treatment. Methods Consecutive 404 advanced HCC patients receiving sorafenib were retrospectively enrolled. All patients were in Child-Pugh class A and BCLC stage C with either portal vein invasion or extrahepatic metastasis at the beginning of sorafenib treatment. Radiologic evaluation based on mRECIST criteria and clinical assessments with compliance were performed on schedule. Results During the median follow-up period of 5.8 months, 310 patients developed progressive disease (PD) and 350 deaths occurred. The PD patients were randomized into derivation and validation cohorts by a 1:1 ratio. The independent predictors of poor PPS in derivation cohort were ALBI grade 3 at PD (hazard ratio [HR]=3.24, p=0.002), new extrahepatic lesions (NEH) (HR=1.75, p=0.011), and early PD within 4 months (HR=1.88, p=0.037). ALBI-PD criteria were proposed by incorporating these three risk factors. In the validation cohort, PPS could be independently predicted by presence of early PD, NEH as well as ALBI grade 3 at PD. Patients within ALBI-PD criteria had significant longer median PPS than those beyond it even in Child-Pugh A (9.7 vs. 4.9 months, p=0.005) subpopulations. Conclusions ALBI-PD criteria can differentiate PPS and stratify the patients with advanced HCC for the second-line trials or salvage therapy. This article is protected by copyright. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|